2025-01-21 - Analysis Report
## Johnson & Johnson (JNJ) Stock Review

**1. Performance vs. S&P 500 (VOO):**

Johnson & Johnson is a multinational corporation that manufactures medical devices, pharmaceuticals, and consumer packaged goods.  The cumulative return of JNJ is 25.49%, significantly lagging behind the S&P 500's cumulative return of 118.37%.  The provided data shows a substantial divergence of -92.9%, placing it at the 5.2nd percentile relative to its historical performance against the S&P 500.  This indicates JNJ's underperformance relative to the broader market.


**2. Recent Price Movement:**

* **Closing Price:** $147.03
* **5-Day Moving Average:** $145.80
* **20-Day Moving Average:** $144.70
* **60-Day Moving Average:** $150.83

The price is currently below all three moving averages, suggesting a bearish trend.  The recent price drop of -$0.50 (-0.34%) shows a small negative daily movement.


**3. Technical Indicators and Expected Return:**

* **RSI:** 54.03 (Slightly above neutral; neither overbought nor oversold)
* **PPO:** 0.48 (Positive, suggesting bullish momentum, but relatively weak)
* **20-Day Relative Divergence Change:** -1.7% (Short-term bearish trend)
* **Expected Return (2+ years):** -510.9% (This is a remarkably negative figure and needs further investigation.  It likely represents a significant underperformance relative to the S&P 500 over the long term, given the current trend and the previous analysis, potentially suggesting an error in the calculation or a very pessimistic forecast.)


**4. Recent Earnings Analysis:**

| Date       | EPS    | Revenue      |
|------------|--------|---------------|
| 2024-10-23 | $1.12  | $22.47B       |
| 2024-07-25 | $1.95  | $22.45B       |
| 2024-05-01 | $1.35  | $21.38B       |
| 2024-02-16 | $1.68  | $21.39B       |
| 2023-10-27 | $10.32 | $21.35B       |

**Analysis:**  There's a significant drop in EPS from Q4 2023 ($10.32) to subsequent quarters.  This needs further investigation to determine the cause (e.g., one-time events, changes in accounting, seasonal factors, or underlying business performance issues). Revenue has remained relatively stable around $21-22.5B. The unusually high EPS in Q4 2023 requires further scrutiny.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue     | Profit Margin |
|---------|-------------|---------------|
| 2024-09-30 | $22.47B    | 69.01%        |
| 2024-06-30 | $22.45B    | 69.40%        |
| 2024-03-31 | $21.38B    | 69.55%        |
| 2023-12-31 | $21.39B    | 68.23%        |
| 2023-09-30 | $21.35B    | 69.06%        |

**Capital and Profitability:**

| Quarter | Equity      | ROE    |
|---------|-------------|--------|
| 2024-09-30 | $70.16B    | 3.84%  |
| 2024-06-30 | $71.54B    | 6.55%  |
| 2024-03-31 | $70.02B    | 4.65%  |
| 2023-12-31 | $68.77B    | 5.89%  |
| 2023-09-30 | $71.23B    | 36.54% |


**Analysis:** Revenue remains relatively stable, with consistent high profit margins.  However, ROE shows volatility, with a particularly high value in Q3 2023 (36.54%) that requires explanation.  The drop in ROE needs to be investigated.



**7. Overall Analysis:**

JNJ is currently underperforming the S&P 500 significantly. While revenue and profit margins remain strong, the recent earnings report reveals concerning EPS volatility and needs further investigation.  The unusually high EPS and ROE in Q4 2023 demand additional clarification.  The -510.9% projected long-term return is alarming and likely erroneous.  Technical indicators suggest a weak bullish momentum, but the price is trending downwards.  Further research is needed to understand the reasons behind the substantial underperformance and the unusual figures in the earnings report before making any investment decisions.  The provided data alone isn't sufficient to provide a strong buy or sell recommendation.

**8. Disclaimer:** This analysis is based solely on the provided data and should not be considered financial advice.  Conduct thorough due diligence and consult with a financial advisor before making any investment decisions.
